Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ana Isabel Martin-Quesada

Showing results (1-10 of 3) with videos related to

Pageof 1
Sort By:
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|August 2, 2024
Charting cancer's course: revealing the role of diet, exercise, and the microbiome in cancer evolution and immunotherapy responseAna Isabel Martin-Quesada, Maeve A Hennessy, Ana Cardeña Gutiérrez
Journal for Immunotherapy of Cancer|November 28, 2025
Second-event endpoints (EFS2, PRFS2 and PFS2) after anti-PD-(L)1-based RCTs: a systematic review and meta-analysisPablo Jimenez-Labaig, Oriol Mirallas, Ana Isabel Martin-Quesada, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|March 21, 2024
Comparative study of weekly and three-weekly neoadjuvant carboplatin in triple-negative breast cancer: retrospective analysis in real-world settingsAna Isabel Martin-Quesada, Elisenda Llabres-Valentí, Cristina María Montesdeoca-Godoy, et al.
Pageof 1

Showing results (1-10 of 3) with videos related to

Sort By:
Pageof 1
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|August 2, 2024
Charting cancer's course: revealing the role of diet, exercise, and the microbiome in cancer evolution and immunotherapy responseAna Isabel Martin-Quesada, Maeve A Hennessy, Ana Cardeña Gutiérrez
Journal for Immunotherapy of Cancer|November 28, 2025
Second-event endpoints (EFS2, PRFS2 and PFS2) after anti-PD-(L)1-based RCTs: a systematic review and meta-analysisPablo Jimenez-Labaig, Oriol Mirallas, Ana Isabel Martin-Quesada, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|March 21, 2024
Comparative study of weekly and three-weekly neoadjuvant carboplatin in triple-negative breast cancer: retrospective analysis in real-world settingsAna Isabel Martin-Quesada, Elisenda Llabres-Valentí, Cristina María Montesdeoca-Godoy, et al.
Pageof 1